Mudawi Dalal, Taha Salma, Ibrahim Yaldez, Omar Mervat, Mobayed Hassan
Allergy and Immunology Division, Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail:
Qatar Med J. 2022 Apr 1;2022(2):10. doi: 10.5339/qmj.2022.fqac.10. eCollection 2022.
Unverified penicillin allergy has been linked to adverse patient events and increased healthcare expenditure owing to the usage of broad-spectrum, expensive antibiotics. Penicillin allergy test is the gold standard to diagnose penicillin allergy; and in this study, we present data from Qatar which have not been published before.
Patients with a history of penicillin allergy who underwent penicillin allergy testing between January 2015 and December 2020 at the Allergy Division of the Hamad General Hospital were retrospectively reviewed from the division registry. Benzylpenicilloyl-polylysine (PPL) and minor determinant mixture (MDM) kit DAP-penicillin (0.04 mg +0.5 mg)/vial) (penicillin G, amoxicillin (20 mg/vial), and lately clavulanic acid (20 mg/vial) (DAP, Diater, Madrid, Spain) were used for skin and intradermal testing according to published guidelines. Patients with negative skin tests were administered direct oral challenge with amoxicillin/clavulanate (500/125 mg) and observed for 2 hours.
Of the 189 charts reviewed, 183 patients had a complete data set for analysis. Patients were predominantly women (n = 132, 72%) with an average age of 42 years. Of these patients, 149 (81.4%) had a history of an immediate allergic reaction to penicillin, 10 had a history of delayed reactions, and 24 had other or undefined reactions. A total of 39 (21.3%) patients were diagnosed with penicillin allergy (30 patients with positive skin test results and 9 using a direct oral challenge). Of the 30 patients with positive skin testing, 5 reacted to PPL, 8 to MDM, 13 to amoxicillin, and 4 to clavulanic acid.
Previous studies indicate that 90% patients with a history of penicillin allergy were able to tolerate the drug (10% were truly allergic). Our data showed that 21% were truly allergic to penicillin. This high positive rate can be attributed to the high pretest probability based on the detailed history obtained before the test, which led to the exclusion of patients with symptoms incompatible with penicillin allergy from the test.
未经证实的青霉素过敏与不良患者事件相关,并且由于使用广谱、昂贵的抗生素而导致医疗保健支出增加。青霉素过敏试验是诊断青霉素过敏的金标准;在本研究中,我们展示了来自卡塔尔的此前未发表的数据。
对2015年1月至2020年12月期间在哈马德总医院过敏科接受青霉素过敏试验的有青霉素过敏史的患者,从科室登记处进行回顾性分析。根据已发表的指南,使用苄青霉素酰聚赖氨酸(PPL)和次要决定簇混合物(MDM)试剂盒DAP - 青霉素(0.04毫克 + 0.5毫克)/瓶)(青霉素G、阿莫西林(20毫克/瓶)以及最近的克拉维酸(20毫克/瓶)(DAP,Diater,马德里,西班牙)进行皮肤和皮内试验。皮肤试验阴性的患者给予阿莫西林/克拉维酸(500/125毫克)直接口服激发试验,并观察2小时。
在审查的189份病历中,183例患者有完整的数据集用于分析。患者以女性为主(n = 132,72%),平均年龄42岁。在这些患者中,149例(81.4%)有青霉素速发型过敏反应史;10例有迟发型反应史;24例有其他或不明反应史。共有39例(21.3%)患者被诊断为青霉素过敏(30例皮肤试验结果阳性,9例通过直接口服激发试验诊断)。在30例皮肤试验阳性的患者中,5例对PPL有反应,8例对MDM有反应,13例对阿莫西林有反应,4例对克拉维酸有反应。
先前的研究表明,90%有青霉素过敏史的患者能够耐受该药物(10%为真正过敏)。我们的数据显示,21%的患者对青霉素真正过敏。这种高阳性率可归因于基于试验前获得的详细病史的高预试验概率,这导致将与青霉素过敏症状不符的患者排除在试验之外。